Who are Amolyt Pharma's investors?

Amolyt Pharma's investors include Andera Partners, CTI Life Sciences Fund L.P., EQT Life Sciences, Kurma Partners, LSP (Life Sciences Partners), Octalfa, Sofinnova Partners, Intermediate Capital Group and 3 more.

Amolyt Pharma

21 known investors

Find your way into Amolyt Pharma

Your email: who you already know at Amolyt Pharma, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Amolyt Pharma team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Developing therapeutic peptides targeting rare endocrine diseases (past investment).

Investors · 21

Andera Partnerslisted by Andera PartnersParis

How we know: Andera Partners's portfolio page · a partner's Signal profile · sofinnovapartners.com · globenewswire.com · Not right? Tell us

CTI Life Sciences Fund L.P.listed by CTI Life Sciences Fund L.P.Montréal

How we know: CTI Life Sciences Fund L.P.'s portfolio page · Not right? Tell us

EQT Life Scienceslisted by EQT Life SciencesLuxembourg · $11M – $66M

How we know: EQT Life Sciences's portfolio page · a partner's Signal profile · sofinnovapartners.com · Not right? Tell us

Kurma Partnerslisted by Kurma PartnersParis · $162K – $10.8M

How we know: Kurma Partners's portfolio page · a partner's Signal profile · sofinnovapartners.com · the VCSheet dataset · Not right? Tell us

LSP (Life Sciences Partners)listed by LSP (Life Sciences Partners)Amsterdam · $11M – $66M

How we know: LSP (Life Sciences Partners)'s portfolio page · Not right? Tell us

Octalfalisted by OctalfaLyon · $108K – $2.7M

How we know: Octalfa's portfolio page · Not right? Tell us

Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · sofinnovapartners.com · Not right? Tell us

Intermediate Capital GroupreportedLondon · $5M – $50M

How we know: sofinnovapartners.com · Not right? Tell us

Mass General Brigham VenturesreportedBoston

How we know: sofinnovapartners.com · Not right? Tell us

OrbiMedreportedNew York · $1M – $75M

How we know: sofinnovapartners.com · Not right? Tell us

Sectoral Asset ManagementreportedMontreal

How we know: sofinnovapartners.com · globenewswire.com · Not right? Tell us

Also in the syndicate · 10

ATEMATEM CapitalCredit Agricole CreationCTI Life SciencesInnobio 2 managed by Bpifrance InvestissementLSPNovo Holdings (Novo Ventures)PontifaxRelyens Innovation Santé/Turenne CapitalTekla Capital Investment LLC

Funding

SEC filings, press & company announcements

Undisclosed amountSeries CJan 2023
Intermediate Capital Group (lead), Sofinnova Partners (lead), Andera Partners, ATEM, Credit Agricole Creation, CTI Life Sciences, EQT Life Sciences, Innobio 2 managed by Bpifrance Investissement, Kurma Partners, Mass General Brigham Ventures, Novo Holdings (Novo Ventures), Orbimed, Pontifax, Relyens Innovation Santé/Turenne Capital, Sectoral Asset Management, Tekla Capital Investment LLC
Source ↗
Undisclosed amountSeries BSep 2021
Andera Partners (lead), Sectoral Asset Management (lead), ATEM Capital, LSP
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Amolyt Pharma raises $138M Series C led by Sofinnova — Sofinnova Partnerssofinnovapartners.com · Jan 2023

Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partnersglobenewswire.com · Sep 2021

Frequently asked questions

What does Amolyt Pharma do?: Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Who are Amolyt Pharma's investors?: Amolyt Pharma's investors include Andera Partners, CTI Life Sciences Fund L.P., EQT Life Sciences, Kurma Partners, LSP (Life Sciences Partners), Octalfa, Sofinnova Partners, Intermediate Capital Group and 3 more.